References

Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives

10.6004/jnccn.2012.0018 · 2012 · External reference

Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review

10.1016/j.critrevonc.2015.12.001 · 2016 · External reference

Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment

10.1200/jco.2006.05.6382 · 2006 · External reference

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

10.1038/bjc.1997.507 · 1997 · External reference

Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends

2021 · External reference

Preference weights for chemotherapy side effects from the perspective of women with breast cancer

10.1007/s10549-013-2727-3 · 2013 · External reference

Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer

2005 · External reference

Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis

10.2147/ppa.s80327 · 2015 · External reference

Self-reported adherence to capecitabine on XELOX treatment as adjuvant therapy for colorectal cancer

10.3727/096504017x15012905098071 · 2017 · External reference

Antiemetics: ASCO guideline update

10.1200/jco.20.01296 · 2020 · External reference

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

10.1016/j.esmoop.2023.102195 · 2024 · External reference

2023 Japan Society of Clinical Oncology clinical practice guidelines update for antiemesis

10.1007/s10147-024-02535-x · 2024 · External reference

2023 updated MASCC/ESMO Consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents

2023 · External reference

Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial

10.1016/j.ejca.2015.03.024 · 2015 · External reference

Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial

2021 · External reference

Clinical Efficacy of Aprepitant in patients with gynecological cancer after chemotherapy using paclitaxel and carboplatin

2015 · External reference

Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists

2011 · External reference

Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis

10.1007/s12032-018-1199-z · 2018 · External reference

Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer

10.1186/s40780-021-00204-z · 2021 · External reference

Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213

2020 · External reference

Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates

10.1080/14796694.2025.2479417 · 2025 · External reference

Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis

2023 · External reference

Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC)

1998 · External reference

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

10.1093/annonc/mdg417 · 2003 · External reference

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

10.1002/cncr.11817 · 2003 · External reference

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy

10.1200/jco.2005.09.050 · 2005 · External reference

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

2010 · External reference

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial

10.1093/annonc/mdv482 · 2016 · External reference

Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy

10.1002/cncr.30054 · 2016 · External reference

10.1016/s1470-2045(15)00034-0

10.1016/s1470-2045(15)00034-0 · 2015 · External reference

10.1007/s10147-015-0928-y

10.1007/s10147-015-0928-y · 2016 · External reference

Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: a randomized, open-label, phase 3 trial

10.1016/j.eclinm.2022.101480 · 2022 · External reference

10.1002/cncr.24630

10.1002/cncr.24630 · 2009 · External reference

Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer

10.1016/j.lungcan.2015.11.009 · 2015 · External reference

A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy

10.1038/bjc.2013.400 · 2013 · External reference

Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients

10.3332/ecancer.2015.567 · 2015 · External reference

Doublet or triplet antiemetic prophylaxis for nausea and vomiting induced by trastuzumab deruxtecan: an open-label, randomized, and multicenter exploratory phase 2 study

10.7150/jca.87169 · 2023 · External reference

A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan: the EN-hance study

10.1007/s10147-025-02748-8 · 2025 · External reference

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

10.1093/annonc/mdu101 · 2014 · External reference

Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy

10.1002/cam4.6121 · 2023 · External reference

Olanzapine as antiemetic prophylaxis in moderately emetogenic chemotherapy: a phase 3 randomized clinical trial

10.1001/jamanetworkopen.2024.26076 · 2024 · External reference

Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: a multi-institution phase II study

10.1016/j.ygyno.2020.01.004 · 2020 · External reference

Low-dose olanzapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic malignancies: a prospective multicenter phase II trial

10.1002/onco.13772 · 2021 · External reference

10.1016/j.annonc.2024.09.001

10.1016/j.annonc.2024.09.001 · 2025 · External reference

Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: a prospective multicenter phase II trial

10.1016/j.lungcan.2024.107801 · 2024 · External reference

Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy

10.1093/annonc/mdp584 · 2010 · External reference

Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial

2011 · External reference

Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial

2019 · External reference

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

2010 · External reference

Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan

10.1007/s10147-015-0786-7 · 2015 · External reference

Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis

10.1111/cas.12146 · 2013 · External reference

Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group

10.1200/jco.1997.15.1.116 · 1997 · External reference

Beyond the usual window: persistent nausea with trastuzumab deruxtecan calls for new management strategies

10.1016/j.annonc.2024.10.017 · 2025 · External reference

Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE

10.1200/jco.21.01315 · 2022 · External reference

Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

10.1016/j.ejca.2025.115451 · 2025 · External reference

Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging

10.1038/clpt.2012.62 · 2012 · External reference

Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting: a short review and clinical perspective

10.1007/s12325-023-02474-5 · 2023 · External reference

A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC

10.1002/cncr.34088 · 2022 · External reference

Study protocol for a prospective observational study to evaluate the efficacy of fosnetupitant for long-delayed chemotherapy-induced nausea and vomiting in patients receiving platinum-based chemotherapy (LODEC-N)

2023 · External reference